Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Eliquis

- PMLiVE

Bristol Myers Squibb presents positive results for idiopathic pulmonary fibrosis drug

About 100,000 people are living with the progressive condition in the US alone

- PMLiVE

Bristol Myers Squibb’s Sotyktu approved by MHRA for plaque psoriasis

Up to 1.8 million people in the UK are affected by some form of the inflammatory condition

- PMLiVE

Bristol Myers Squibb and Tubulis partner in deal worth over $1bn

The agreement is aimed at developing differentiated ADCs for solid tumours

- PMLiVE

Bristol Myers Squibb’s Sotyktu approved by EC for plaque psoriasis

At least 100 million people worldwide are impacted by some form of psoriasis

- PMLiVE

BMS reports positive three-year results for Opdivo to treat bladder cancer

Urothelial carcinoma accounts for approximately 90% of bladder cancer cases

- PMLiVE

BMS, Exelixis and Ipsen report three-year results for combination treatment in kidney cancer

Renal cell carcinoma accounts for more than 431,000 new cases and 179,000 deaths each year

- PMLiVE

BMS and 2seventy bio report positive phase 3 results for multiple myeloma treatment

An estimated 35,000 new cases of multiple myeloma will be diagnosed in the US this year

- PMLiVE

Bristol Myers Squibb’s plaque psoriasis treatment recommended by CHMP

At least 100 million people worldwide are impacted by some form of psoriasis

- PMLiVE

Bristol Myers Squibb’s Opdivo recommended by NICE for rare gastroesophageal cancers

The PD-1 inhibitor demonstrated a statistically significant benefit in overall survival

- PMLiVE

BMS’s Reblozyl meets primary endpoint in myelodysplastic syndromes phase 3 trial

The study showed significant improvements in red blood cell transfusion independence

- PMLiVE

BMS confirms COVID-19 vaccine immune response in Zeposia-treated MS patients

Over 92% of patients in the analyses mounted a serological response following vaccination

- PMLiVE

Bristol Myers Squibb’s Opdivo shows promise as adjuvant melanoma treatment

The PD-1 inhibitor demonstrated a statistically significant benefit in recurrence-free survival

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links